

27 West Morten Avenue
Phoenix, AZ 85021-7246
phone (602) 618-0183 · fax (602) 926-8109
programs@askican.org · www.askican.org

3944 Pine Avenue
Long Beach, CA 90807
phone (562) 427-5561

ICAN Boards and Councils

Founding Chairman
Sidney M. Rosen, Esq.

Chairman, Board of Trustees
Sherry Weinstein

President and CEO
Marcia K. Horn, JD

*Chairman, Physicians Advisory Council and
Health Information Technology Council*
Robert H. Tamis, MD

Chairman, Board Governance
Carey Gregory

Chairman, Advisory Council
Cathy Dalzell

Honorary Chair, Board of Trustees
Cheryl J. Hintzen-Gaines

*Honorary Co-Chairmen, International
Corporate Advisory Council*
Kevin M. Hanlon and Robert T. Hanlon, PhD

Honorary Chair, International Board
Marc Mondavi

*Director, Research Services and Strategic
Planning*
Regina Marie Klopfer

Director, Global Volunteer Resources
Andrew Young

Director, Diversity and Equity Advocacy
Andrew J. Brown, Jr.

Chairman, Texas Board of Advisors
Chuck Clayton

Chairman, Scientific Advisory Council
G. Robert Pettit, PhD

Chairman, Biomarkers Council
Scott M. Kahn, PhD

Surgical Oncology Advisory Council
Björn Brücher, MD, FRCS, FACS, Chairman
Jeffrey M. Farma, MD
Richard J. Gray, MD
Barbara A. Pockaj, MD

Medical Oncology Council
John S. Link, MD, Chairman
Michael S. Gordon, MD
Jeffrey D. Isaacs, MD
Robert A. Nagourney, MD
Michael S. Roberts, MD

*Anatomic Pathology and
Molecular Diagnostics Council*
Anthony M. Magliocco, MD, Chairman
Arthur E. Sitelman, MD
Qingmei Xie, MD



Testimony of Steve Horn Director of Governmental Relations ICAN, International Cancer Advocacy Network

February 22, 2021

Re: Supporting SB 439, Relating to the Cost of Prescription Drugs (Senator Knopp)

Good Afternoon Chair Patterson and Members of the Committee,

My name is Steve Horn. I am the Director of Governmental Relations for ICAN, International Cancer Advocacy Network, testifying in support of SB 439.

ICAN is a 501(c)(3) non-profit organization, based in Phoenix, Arizona. During the past 25 years, ICAN has helped over 14,000 cancer patients find clinical trials and new therapies. We have helped patients in Oregon, in all 50 states, and in 54 foreign countries. Most of the patients we help are Stage IV, the most serious stage of cancer.

When we look at legislation, whether at the state or federal level, we ask two basic questions:

- 1) Does it increase patient access to a potential treatment?
- 2) Does it reduce patient costs (which often increases access)?

SB 439 meets both tests. Requiring that patients receive 85% of rebates from pharmaceutical companies will help patients access critically needed, life-extending and life-saving drugs. On behalf of ICAN's Oregon patients, we thank Senator Knopp for sponsoring this legislation, and we urge you to support SB 439 throughout the legislative process until it is signed into law. Thank you.

ICAN is a 501(c)(3) tax-exempt charitable organization (EIN 86-0818253) serving Stage IV metastatic cancer patients across the United States and in 54 countries since 1996. ICAN is one of the few national cancer organizations that is both Platinum-rated on GuideStar (the highest rating), and five-star rated on Great Nonprofits (also the highest).

ICAN, operating with strict standards of board governance, has received the "Top-Rated Health Care Nonprofit" award from Great Nonprofits every year since 2010.